Trending Now - Researchers Discover Brain Pathway Linked to GLP-1 Weight Loss

WHO:

Ground News - Researchers from the National Institutes of Health (NIH) and the University of Colorado Anschutz, including assistant professor Allison Shapiro and physician-scientist Lorenzo Leggio.

Yahoo - Study participants included 13 teens and young women with a hormonal disorder affecting the ovaries.

WHAT:

ScienceAlert - A study presented at the European Congress on Obesity (ECO 2026) found that patients who lost 15 percent or more of their body mass index (BMI) while taking GLP-1 drugs had a 37 percent lower risk of osteoarthritis, a 30 percent lower risk of chronic kidney disease, a 69 percent lower risk of obstructive sleep apnea, and a 32 percent lower risk of heart failure.

Yahoo - The study found that brain connections in the salience network multiplied within only a few months of using GLP-1 drugs, indicating extensive changes.

Yahoo - Study participant Grace Hamilton, a 28-year-old from outside of Denver, lost over 100 pounds on GLP-1s and reported that her testosterone levels are more regulated.

Yahoo - Hamilton stated that since being on GLP-1s, she no longer needs antidepressants and has shifted from being a social drinker to not having a desire to drink at all.

Ground News - A new NIH-funded study shows that oral GLP-1 drugs suppress hedonic eating through a deep-brain reward circuit linked to dopamine release.

Yahoo - The study found extensive changes in brain connections in the salience network among participants after a few months of using GLP-1 drugs.

Yahoo - Tens of millions of people are taking GLP-1 medications worldwide, which are being studied for effects on addiction, cognition, neurodegeneration, motivation, and pleasure.

Yahoo - Eli Lilly is conducting a large clinical trial to examine whether tirzepatide can help treat alcohol-use disorder, expected to conclude by the end of this year or early next year.

Yahoo - Several major studies are underway examining GLP-1 drugs on nicotine dependence, opioid- and cocaine-use disorders, gambling addiction, and binge eating.

WHERE:

Yahoo - The research was conducted at the University of Colorado Anschutz.

WHEN:

ScienceAlert - The health records of 89,718 individuals were analyzed for those who started GLP-1 or GLP-1/GIP drugs between January 2021 and June 2024.

Yahoo - The clinical trial by Eli Lilly is expected to conclude by the end of this year or early next year.

WHY:

Yahoo - Researchers are investigating whether GLP-1 drugs might prove more useful earlier in the treatment process, potentially delaying or preventing diseases like Alzheimer’s.

Yahoo - Researchers are investigating GLP-1 drugs due to their potential effects on brain systems involved in reward, craving, and motivation, which could help in treating addiction.

HOW:

Yahoo - Researchers are studying how GLP-1 drugs may affect brain circuits involved in emotion, desire, and cognition, indicating a shift in understanding the drugs' impact beyond appetite control.

Ground News - The study utilized brain scans to catalogue the effects of GLP-1 drugs on participants' brains before and after treatment.

Yahoo - GLP-1 drugs mimic hormones involved in appetite, blood sugar, and digestion, and are believed to influence brain function by reducing inflammation and improving metabolism.

(UPDATED May 29, 2026 18:04 UTC)

A significant study presented at the European Congress on Obesity found that patients who lost 15 percent or more of their body mass index while taking GLP-1 drugs experienced a remarkable decrease in health risks. Specifically, these individuals had a 37 percent lower risk of osteoarthritis, a 30 percent lower risk of chronic kidney disease, a 69 percent lower risk of obstructive sleep apnea, and a 32 percent lower risk of heart failure. The analysis was based on health records from 89,718 individuals who began using GLP-1 or GLP-1/GIP drugs between January 2021 and June 2024.

(UPDATED May 29, 2026 16:16 UTC)

A new study has revealed that brain connections in the salience network significantly increased within just a few months of using GLP-1 drugs, suggesting extensive changes in brain function. One participant, Grace Hamilton, a 28-year-old from outside Denver, lost over 100 pounds and reported improvements in her testosterone levels, stating she no longer needs antidepressants and has lost her desire to drink alcohol. Researchers are now exploring whether these drugs could be more effective earlier in treatment to potentially delay or prevent diseases like Alzheimer’s, as they investigate their impact on brain circuits related to emotion, desire, and cognition.

(UPDATED May 29, 2026 14:02 UTC)

A new study funded by the NIH and conducted at the University of Colorado Anschutz reveals that oral GLP-1 drugs can suppress hedonic eating by affecting deep-brain reward circuits linked to dopamine release. The research, which involved 13 teens and young women with a hormonal disorder, showed significant changes in brain connections within the salience network after a few months of using these medications. Eli Lilly is also running a large clinical trial to determine if tirzepatide can aid in treating alcohol-use disorder, with results expected by the end of this year or early next year.